HIMS 他的討論區（2）

都係果句，hims 又唔係得glp1，亦唔洗一定要靠glp1 發展業務

咁想hims 收皮， 你咪allin put

跟住跌咩玩法

我自己會under 19先考慮加倉

跌到

就講就到

19 蚊喇樓豬

又黎

就嚟拍得住smci

加咗

What Happened: A report from the FDA on Wednesday shows that all doses of Novo Nordisk's Ozempic and Wegovy, both GLP-1 receptor agonists, are now available. The change comes after a prolonged shortage of these drugs, which drove demand for compounded versions.

Semaglutide, the active ingredient in both drugs, has been on the FDA's shortage list for over two years. During that time, compounding pharmacies — like those serving Hims & Hers — were legally allowed to create less expensive, compounded versions.

Hims & Hers stock had previously benefited from the demand for compounded GLP-1 injections and experienced a boost when the company entered this market.

The FDA's announcement suggests Novo Nordisk may soon meet demand, potentially removing Ozempic and Wegovy from the shortage list. Without a shortage, compounding pharmacies may lose the regulatory allowance to produce these alternatives. This may directly impact revenue for companies like Hims & Hers that rely on sales of compounded versions.

lly出新聞爆升 佢跌
lly跌又跟住爆跌

屌佢老母
不過是但，當係有位加
唔知下個星期er 點

尋晚本身想入呢隻
跟住跌左 7%

今晚er

ER都幾勁

樓豬你隻alab 升左20%

4x入咗